Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
17.48
-0.48 (-2.67%)
At close: May 13, 2025, 4:00 PM
17.49
+0.01 (0.06%)
Pre-market: May 14, 2025, 7:05 AM EDT
Teva Pharmaceutical Revenue
Teva Pharmaceutical had revenue of $3.89B in the quarter ending March 31, 2025, with 1.89% growth. This brings the company's revenue in the last twelve months to $16.62B, up 3.82% year-over-year. In the year 2024, Teva Pharmaceutical had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
$16.62B
Revenue Growth
+3.82%
P/S Ratio
1.19
Revenue / Employee
$451,154
Employees
36,830
Market Cap
20.05B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TEVA News
- 5 days ago - Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside - Seeking Alpha
- 6 days ago - Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says - Barrons
- 6 days ago - Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum - Benzinga
- 6 days ago - Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Teva Pharm first-quarter profit rise tops estimates - Reuters
- 7 days ago - Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved - GlobeNewsWire
- 7 days ago - Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City - GlobeNewsWire
- 8 days ago - Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? - Benzinga